GXE Stock Overview
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Galapagos NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €27.14 |
| 52 Week High | €41.28 |
| 52 Week Low | €27.14 |
| Beta | 0.021 |
| 1 Month Change | -10.58% |
| 3 Month Change | -20.32% |
| 1 Year Change | -19.56% |
| 3 Year Change | -60.47% |
| 5 Year Change | -72.79% |
| Change since IPO | 279.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| GXE | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.2% | -4.9% | -1.5% |
| 1Y | -19.6% | -19.9% | 0.9% |
Return vs Industry: GXE matched the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: GXE underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| GXE volatility | |
|---|---|
| GXE Average Weekly Movement | 3.3% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GXE's share price has been volatile over the past 3 months.
Volatility Over Time: GXE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 1,123 | Paul Stoffels | www.glpg.com |
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l.
Galapagos NV Fundamentals Summary
| GXE fundamental statistics | |
|---|---|
| Market cap | €1.80b |
| Earnings (TTM) | -€3.99m |
| Revenue (TTM) | €239.72m |
7.5x
P/S Ratio-452.4x
P/E RatioIs GXE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GXE income statement (TTM) | |
|---|---|
| Revenue | €239.72m |
| Cost of Revenue | €241.29m |
| Gross Profit | -€1.57m |
| Other Expenses | €2.42m |
| Earnings | -€3.99m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -0.061 |
| Gross Margin | -0.65% |
| Net Profit Margin | -1.66% |
| Debt/Equity Ratio | 0% |
How did GXE perform over the long term?
See historical performance and comparison